Regeneron Pharmaceuticals has announced it will lower the pricing of its drugs under the Medicaid program and plans to align drug prices in the US market with those in other countries in the future.

This strategic adjustment marks a significant shift in the pricing policy of the biotechnology giant. The company stated that by lowering Medicaid prices, it will improve drug accessibility; while the long-term goal of aligning prices with international standards aims to address ongoing criticism about high drug prices in the United States. Analysts pointed out that this move could have a profound impact on the biopharmaceutical industry and may prompt other companies to reassess their pricing models. Regeneron's core products include Eylea, which treats eye diseases, and Dupixent, an eczema medication—both blockbuster drugs whose pricing in the U.S. market has always attracted attention.